A series of clinical trials examining biomarkers to reduce cancer deaths by around 20% could revolutionize cancer care. What does this mean for insurers?
A series of clinical trials examining biomarkers to reduce cancer deaths by around 20% could revolutionize cancer care. What does this mean for insurers?
